Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-frequency daratumumab for AL light chain amyloidosis
ChiCTR2100049253Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of daratumumab in light-chain amyloidosis, sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: overall response rate. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
daratumumab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on ChiCTR2100049253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049253.